Inspire Medical Systems (NYSE:INSP) Stock Rating Lowered by Zacks Research

Inspire Medical Systems (NYSE:INSP) was downgraded by research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research note issued on Wednesday,Zacks.com reports.

Other analysts have also recently issued reports about the stock. Evercore set a $55.00 target price on shares of Inspire Medical Systems in a research report on Tuesday, May 5th. Oppenheimer restated a “market perform” rating on shares of Inspire Medical Systems in a research report on Thursday, May 7th. Wolfe Research cut shares of Inspire Medical Systems from an “outperform” rating to a “peer perform” rating in a research report on Friday, February 13th. JPMorgan Chase & Co. decreased their target price on shares of Inspire Medical Systems from $67.00 to $54.00 and set a “neutral” rating on the stock in a research report on Tuesday, May 5th. Finally, Mizuho decreased their target price on shares of Inspire Medical Systems from $70.00 to $55.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 5th. Four investment analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $85.00.

Inspire Medical Systems Stock Performance

Shares of NYSE INSP opened at $42.65 on Wednesday. The company has a market cap of $1.23 billion, a P/E ratio of 9.50, a P/E/G ratio of 4.33 and a beta of 0.83. The firm’s fifty day moving average is $53.89 and its two-hundred day moving average is $77.66. Inspire Medical Systems has a 52-week low of $41.52 and a 52-week high of $156.82.

Inspire Medical Systems (NYSE:INSP) last posted its earnings results on Monday, May 4th. The company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.38. The firm had revenue of $204.58 million during the quarter, compared to analyst estimates of $200.04 million. Inspire Medical Systems had a net margin of 14.33% and a return on equity of 10.35%. Inspire Medical Systems’s revenue for the quarter was up 1.6% compared to the same quarter last year. During the same period last year, the firm posted $0.10 earnings per share. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. As a group, analysts forecast that Inspire Medical Systems will post 0.91 EPS for the current fiscal year.

Institutional Investors Weigh In On Inspire Medical Systems

Several hedge funds have recently modified their holdings of the business. Xponance Inc. lifted its position in shares of Inspire Medical Systems by 2.9% in the 3rd quarter. Xponance Inc. now owns 4,177 shares of the company’s stock worth $310,000 after purchasing an additional 116 shares during the period. Daiwa Securities Group Inc. lifted its position in Inspire Medical Systems by 38.7% during the second quarter. Daiwa Securities Group Inc. now owns 466 shares of the company’s stock valued at $60,000 after acquiring an additional 130 shares during the last quarter. State of Wyoming lifted its position in Inspire Medical Systems by 31.5% during the fourth quarter. State of Wyoming now owns 731 shares of the company’s stock valued at $67,000 after acquiring an additional 175 shares during the last quarter. Smartleaf Asset Management LLC lifted its position in Inspire Medical Systems by 84.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 449 shares of the company’s stock valued at $42,000 after acquiring an additional 205 shares during the last quarter. Finally, Apollon Wealth Management LLC lifted its position in Inspire Medical Systems by 5.6% during the first quarter. Apollon Wealth Management LLC now owns 3,997 shares of the company’s stock valued at $206,000 after acquiring an additional 212 shares during the last quarter. Hedge funds and other institutional investors own 94.91% of the company’s stock.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.